INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
18 Years and older, Male and Female
INCB 00928-104 (primary)
NCI-2020-08196
Summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in
combination with ruxolitinib in participants with MF who are transfusion-dependent or
presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and
expansion.
Eligibility
- Participants with MF who are transfusion-dependent or present with symptomatic anemia, defined as follows:
- Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3 separate occasions with at least 7 days between measurements (Note: RBC transfusion must be at least 2 weeks before the Hgb measurement during screening).
- Transfusion-dependent: Participant has received at least 4 units of RBC transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has received an average of at least 4 units of RBC transfusions in the 8 weeks immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the absence of bleeding or treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
- 0 or 1 for the dose-escalation stages.
- 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to IWG-MRT criteria.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.